31 Aug 2026, 05:26 UTC≈1,410 views2 reactionsread 17 November 2026 📡 Medscape Medical News Headlines | Food Noise, Weight Stigma, and Managing Obesity
Why doesn’t food noise go quiet for everyone on GLP-1s? Why is the bias against them getting louder? And what does long-term obesity management actually look like?
Medscape Medical News
❤2
31 Aug 2026, 05:26 UTC≈1,380 views1 reactionsread 17 November 2026 📡 Medscape Medical News Headlines | Tailored Approach Shortens Endocarditis Therapy
Tailored antibiotic therapy for infective endocarditis was associated with a significant reduction in treatment duration, according to an open-label multicenter trial.
Medscape Medical News
❤1
31 Aug 2026, 05:26 UTC≈1,290 views2 reactionsread 17 November 2026 📡 Medscape Medical News Headlines | Drug Benefit Seen in Nonobstructive HCM
A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.
Medscape Medical News
❤2
31 Aug 2026, 05:26 UTC≈1,110 viewsread 17 November 2026 📡 Medscape Medical News Headlines | Edoxaban Falls Short After Intracranial Hemorrhage in AF
Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.
Medscape Medical News
31 Aug 2026, 05:26 UTC≈1,020 viewsread 17 November 2026 📡 Medscape Medical News Headlines | Faster 1-Hour MI Rule-Out Is Safe
The 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.
Medscape Medical News
31 Aug 2026, 04:01 UTC961 viewsread 17 November 2026 📡 Medscape Headlines | Tailored Approach Shortens Endocarditis Therapy
Tailored antibiotic therapy for infective endocarditis was associated with a significant reduction in treatment duration, according to an open-label multicenter trial.
Medscape Medical News
31 Aug 2026, 04:01 UTC800 viewsread 17 November 2026 📡 Medscape Headlines | Drug Benefit Seen in Nonobstructive HCM
A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.
Medscape Medical News
31 Aug 2026, 04:01 UTC676 viewsread 17 November 2026 📡 Medscape Headlines | Edoxaban Falls Short After Intracranial Hemorrhage in AF
Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.
Medscape Medical News
31 Aug 2026, 04:00 UTC549 viewsread 17 November 2026 📡 Medscape Headlines | Faster 1-Hour MI Rule-Out Is Safe
The 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.
Medscape Medical News
31 Aug 2026, 04:00 UTC483 viewsread 17 November 2026 📡 Medscape Headlines | Does AF Ablation Work?
Two sham-controlled trials seemingly showed a placebo-resistant benefit to ablation for AF, but the larger SHAM-PVI-AF trial calls those results into question.
theheart.org on Medscape
29 Aug 2026, 21:21 UTC478 viewsread 17 November 2026 📡 Medscape Medical News Headlines | Phase 3 Eplontersen Trial Results Disappoint
Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.
Medscape Medical News
29 Aug 2026, 21:21 UTC428 viewsread 17 November 2026 📡 Medscape Medical News Headlines | Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE
Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.
Medscape Medical News
Showing the 12 most recent of 429 posts we hold for @Medical_journals_and_updates. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.